Glucose Monitor for Endocrine/Metabolic: 76.3% of denials overturned
In 93 California IMR decisions from 2020 to 2025, reviewers overturned 71 (76.3%). In the last five years: 75.8% of 91. 84 were medical-necessity disputes, 9 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 15 | 100.0% |
| 2022 | 9 | 88.9% |
| 2023 | 19 | 78.9% |
| 2024 | 19 | 84.2% |
| 2025 | 29 | 51.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 25 | 88.0% | 76.3% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 8 | 12.5% | 76.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 6 | 33.3% | 76.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for the Dexcom G7 continuous glucose monitor. In this case, the patient manages diabetes with both insulin and a sulfonylurea. The combination of insulin and sulfonylurea increases the risk of hypoglycemia. Based on current medical guidelines, real-time continuous glucose monitoring is recommended in …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for continuous glucose monitor sensors. Recent continuous glucose monitoring systems have evolved beyond traditional blood glucose monitoring by offering both real-time and predictive glycemic metrics. Current leading expert guidelines recommend continuous glucose monitoring for patients with diabetes, particularly those with variable or challenging …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Dexcom G7 continuous glucose monitor sensors. Continuous glucose monitoring is now recognized as a critical tool in the management of type 2 diabetes, not only for patients on intensive insulin regimens but also for patients with poor glycemic control on other therapies. …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a Dexcom 7 glucose monitor plus sensors or a Freestyle Libre 3 glucose monitor with sensors. Per the medical records, the patient has type 2 diabetes mellitus. The patient’s diabetes management regimen does not include insulin. In this clinical setting, given that …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Glucose Monitor denials for Endocrine/Metabolic overturned?
In 93 California IMR decisions from 2020 to 2025, reviewers overturned 71 (76.3%). In the last five years: 75.8% of 91. 84 were medical-necessity disputes, 9 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.